Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...
Zydus Lifesciences: The pharmaceutical company announced the USFDA orphan drug designation to Usnoflast for the treatment of amyotrophic lateral sclerosis. Agro Tech Foods: The CCI approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback